121 related articles for article (PubMed ID: 29792972)
1. Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer.
Kaye DR; Qi J; Morgan TM; Linsell S; Lane BR; Montie JE; Cher ML; Miller DC;
Urology; 2018 Aug; 118():127-133. PubMed ID: 29792972
[TBL] [Abstract][Full Text] [Related]
2. Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer.
Ginsburg KB; Arcot R; Qi J; Linsell SM; Kaye DR; George AK; Cher ML;
J Urol; 2019 May; 201(5):923-928. PubMed ID: 30694939
[TBL] [Abstract][Full Text] [Related]
3. Impact of Early Confirmatory Tests on Upgrading and Conversion to Treatment in Prostate Cancer Patients on Active Surveillance.
Ginsburg KB; Jacobs JC; Qi J; Kaye DR; Eggly SS; Linsell SM; Auffenberg GB; George AK; Montie JE; Cher ML;
Urology; 2021 Jan; 147():213-222. PubMed ID: 32946908
[TBL] [Abstract][Full Text] [Related]
4. The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
Wang M; Qi J; George AK; Semerjian A; Linsell SM; Montie JE; Cher ML; Ginsburg KB;
Prostate; 2022 Jun; 82(10):1068-1074. PubMed ID: 35468226
[TBL] [Abstract][Full Text] [Related]
5. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
[TBL] [Abstract][Full Text] [Related]
6. Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.
Radhakrishnan A; Wallner LP; Skolarus TA; George AK; Rosenberg BH; Abrahamse P; Hawley ST
J Urol; 2022 Sep; 208(3):600-608. PubMed ID: 35522191
[TBL] [Abstract][Full Text] [Related]
7. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
8. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
9. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
Schoots IG; Nieboer D; Giganti F; Moore CM; Bangma CH; Roobol MJ
BJU Int; 2018 Dec; 122(6):946-958. PubMed ID: 29679430
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.
Vargas HA; Akin O; Afaq A; Goldman D; Zheng J; Moskowitz CS; Shukla-Dave A; Eastham J; Scardino P; Hricak H
J Urol; 2012 Nov; 188(5):1732-8. PubMed ID: 23017866
[TBL] [Abstract][Full Text] [Related]
11. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
Amin A; Scheltema MJ; Shnier R; Blazevski A; Moses D; Cusick T; Siriwardena A; Yuen B; van Leeuwen PJ; Haynes AM; Matthews J; Brenner P; O'Neill G; Yuen C; Delprado W; Stricker P; Thompson J
J Urol; 2020 May; 203(5):910-917. PubMed ID: 31825297
[TBL] [Abstract][Full Text] [Related]
12. Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?
Satasivam P; Poon BY; Ehdaie B; Vickers AJ; Eastham JA
J Urol; 2016 Jan; 195(1):74-9. PubMed ID: 26192258
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
14. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
Luckenbaugh AN; Auffenberg GB; Hawken SR; Dhir A; Linsell S; Kaul S; Miller DC;
J Urol; 2017 Mar; 197(3 Pt 1):621-626. PubMed ID: 27663459
[TBL] [Abstract][Full Text] [Related]
15. Age is Associated with Upgrading at Confirmatory Biopsy among Men with Prostate Cancer Treated with Active Surveillance.
Anderson CB; Sternberg IA; Karen-Paz G; Kim PH; Sjoberg D; Vargas HA; Touijer K; Eastham JA; Ehdaie B
J Urol; 2015 Dec; 194(6):1607-11. PubMed ID: 26119671
[TBL] [Abstract][Full Text] [Related]
16. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
[TBL] [Abstract][Full Text] [Related]
17. Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer.
O'Connor LP; Wang AZ; Yerram NK; Lebastchi AH; Ahdoot M; Gurram S; Zeng J; Mehralivand S; Harmon S; Merino MJ; Parnes HL; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Urology; 2020 Oct; 144():164-170. PubMed ID: 32679272
[TBL] [Abstract][Full Text] [Related]
18. The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance.
Yaguchi G; Tang HJ; Deebajah M; Keeley J; Pantelic M; Williamson S; Gupta N; Peabody JO; Menon M; Dabaja A; Alanee S
Urol Oncol; 2020 Jun; 38(6):599.e9-599.e13. PubMed ID: 32265090
[TBL] [Abstract][Full Text] [Related]
19. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?
Hu JC; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Sonn G; Dorey FJ; Marks LS
J Urol; 2014 Aug; 192(2):385-90. PubMed ID: 24512956
[TBL] [Abstract][Full Text] [Related]
20. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
